CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands |
12 Months Ended |
Dec. 31, 2019 |
Dec. 31, 2018 |
Dec. 31, 2017 |
| CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
|
| Net loss |
$ (196,620)
|
$ (139,311)
|
$ (157,945)
|
| Adjustments to reconcile net loss to cash flows from operating activities: |
|
|
|
| Depreciation and amortization |
80,413
|
103,660
|
98,523
|
| Share-based compensation expense |
100,977
|
105,357
|
83,917
|
| Deferred income taxes |
(319)
|
10,623
|
7,234
|
| Change in the fair value of contingent consideration |
22,800
|
19,600
|
(21,600)
|
| Loss on debt refinancing |
|
2,298
|
|
| Payment made for debt refinancing |
|
(2,251)
|
|
| Impairment of property, plant and equipment |
|
5,746
|
|
| Impairment of investment in Synchronicity Pharma, Inc. |
|
|
10,471
|
| Other non-cash charges |
(580)
|
|
|
| Other non-cash charges |
|
979
|
3,471
|
| Changes in assets and liabilities, excluding the effect of acquisitions: |
|
|
|
| Receivables |
35,136
|
(58,632)
|
(42,489)
|
| Contract assets |
(5,156)
|
880
|
|
| Inventory |
(13,077)
|
(2,665)
|
(30,191)
|
| Prepaid expenses and other assets |
(1,784)
|
(5,990)
|
(9,506)
|
| Right-of-use assets |
8,399
|
|
|
| Accounts payable and accrued expenses |
34,847
|
46,739
|
72,658
|
| Contract liabilities |
16,140
|
3,252
|
(1,447)
|
| Operating lease liabilities |
(9,117)
|
|
|
| Other long-term liabilities |
18
|
8,996
|
6,094
|
| Cash flows provided by operating activities |
72,077
|
99,281
|
19,190
|
| CASH FLOWS FROM INVESTING ACTIVITIES: |
|
|
|
| Additions of property, plant and equipment |
(90,942)
|
(69,431)
|
(51,300)
|
| Proceeds from the sale of equipment |
900
|
507
|
162
|
| Proceeds from contingent consideration |
10,000
|
|
|
| Purchases of investments |
(277,518)
|
(397,727)
|
(431,712)
|
| Sales and maturities of investments |
224,602
|
444,456
|
464,494
|
| Acquisition of Rodin Therapeutics, Inc.'s net assets, net of cash acquired |
(8,875)
|
|
|
| Cash flows used in investing activities |
(141,833)
|
(22,195)
|
(18,356)
|
| CASH FLOWS FROM FINANCING ACTIVITIES: |
|
|
|
| Proceeds from the issuance of ordinary shares under share-based compensation arrangements |
18,925
|
20,877
|
23,517
|
| Employee taxes paid related to net share settlement of equity awards |
(9,317)
|
(19,622)
|
(16,433)
|
| Principal payments of long-term debt |
(2,843)
|
(743)
|
|
| Payment made for debt refinancing |
|
(2,132)
|
(3,000)
|
| Cash flows provided by (used in) financing activities |
6,765
|
(1,620)
|
4,084
|
| NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS |
(62,991)
|
75,466
|
4,918
|
| CASH AND CASH EQUIVALENTS—Beginning of period |
266,762
|
191,296
|
186,378
|
| CASH AND CASH EQUIVALENTS—End of period |
203,771
|
266,762
|
191,296
|
| SUPPLEMENTAL CASH FLOW DISCLOSURE: |
|
|
|
| Cash paid for interest |
13,254
|
12,526
|
11,143
|
| Cash paid for taxes |
2,508
|
754
|
2,992
|
| Non-cash investing and financing activities: |
|
|
|
| Purchased capital expenditures included in accounts payable and accrued expenses |
$ 13,789
|
$ 11,720
|
$ 11,151
|